Amarin

Quote
Anonymous said:
What "poker game", BP are laughing at Amarin.
Click to expand...

BP is so desperate for revenue streams that they will pay billions of dollars for anything that has even the smallest value proposition. If you do not think that BP has interest in acquiring Vascepa, fish oil and all, you have absolutely no clue about the industry.

Case in point, BMS purchase of Amylin. BMS offered $22 for Amylin. They said no thanks, diluted their equity only to accept $31 3 months later. Bydureon is similar to Vascepa in many ways, being that neither asset is rare or non-substitutable, but still has marketable aspects.

Companies like AZN are in such dire need of products that they are absolutely "playing poker" with Amarin in effort to get the best price.
 






Amarin will turn out to be a nightmare. The company is in terrible shape and Omega 3 drugs are now thought to be useless. Just look at Lovasa's sales since launch.

If you are over 50, forget applying to any pharma job for the most part.
 






Anonymous said:
BP is so desperate for revenue streams that they will pay billions of dollars for anything that has even the smallest value proposition. If you do not think that BP has interest in acquiring Vascepa, fish oil and all, you have absolutely no clue about the industry.

Case in point, BMS purchase of Amylin. BMS offered $22 for Amylin. They said no thanks, diluted their equity only to accept $31 3 months later. Bydureon is similar to Vascepa in many ways, being that neither asset is rare or non-substitutable, but still has marketable aspects.

Companies like AZN are in such dire need of products that they are absolutely "playing poker" with Amarin in effort to get the best price.
Click to expand...


Maybe I should know this but who is BP?

It may be a joke of a product, but I think working for somebody would be better than working for nobody.
 












"joke of a product"

If you consider Amarin's Anchor Indication (treatment of lowering Trigs between 200/500 for which there is NO current treatment......It's no joke, especially if you are one of these patients. Not to mention, for those patients with over 500 trig score the drug was found to also lower ldl cholesterol while Lovaza increases it.
 






























Anonymous said:
Amarin will turn out to be a nightmare. The company is in terrible shape and Omega 3 drugs are now thought to be useless. Just look at Lovasa's sales since launch.

If you are over 50, forget applying to any pharma job for the most part.
Click to expand...

Very true. The company is in real big trouble. This will prove to be a bad gig.
 












Anonymous said:
Amarin is going down the shitter. Their stock dropped 21% today! This is going to be a very, very bumpy ride! Stay away from this contract!
Click to expand...

Your ignorance of Amarin shows. The drop in stock price was market overreaction to Amarin's CEO announcing that they would move forward with hiring a sales force to launch Vascepa. A lot of shareholders were looking to get rich quick on a 2012 buyout of Amarin. Shareholders are still going to make a huge ROI, they just have to wait a little longer now.
 


















Congrats to those receiving offers. I have been invested in Amarin for some time and I really think they have great management and a great product. I hope there is not age discrimination here, I think the market is just flooded with qualified sales reps. I don't care about this drop in Price per share as this will come back either through buyout or future sales. 1 in 5 adults have triglycerides > 200 and many do not take Loveza because it raises cholesterol. Vascepa will be a blockbuster. Buy some stock. THe share price is now ridiculously low. GLTA.
 












Anonymous said:
Congrats to those receiving offers. I have been invested in Amarin for some time and I really think they have great management and a great product. I hope there is not age discrimination here, I think the market is just flooded with qualified sales reps. I don't care about this drop in Price per share as this will come back either through buyout or future sales. 1 in 5 adults have triglycerides > 200 and many do not take Loveza because it raises cholesterol. Vascepa will be a blockbuster. Buy some stock. THe share price is now ridiculously low. GLTA.
Click to expand...

Yeah, wish I had gotten this position. Notwithstanding all the naysayers on this thread, I am convinced I could have jumped all over Lovaza's business with Vascepa. I would be tempted to buy some stock myself, except I needed to get a job to have discretionary income to invest!
 
























Top Bottom
Back
Quote